A5005166350- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Mesenchymal stem cell research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Virus-based gene therapy research
- Retinoids in leukemia and cellular processes
- CRISPR and Genetic Engineering
- Viral-associated cancers and disorders
- T-cell and B-cell Immunology
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- RNA Interference and Gene Delivery
- Angiogenesis and VEGF in Cancer
- Bone and Joint Diseases
- Neutropenia and Cancer Infections
- Polyomavirus and related diseases
- Nanowire Synthesis and Applications
- Antifungal resistance and susceptibility
- Blood disorders and treatments
- Hepatitis B Virus Studies
Teikyo University
2014-2025
Weatherford College
2022
Baylor College of Medicine
2015-2020
Takezono Higashi Elementary School
2019
Houston Methodist
2015-2018
Methodist Hospital
2015-2018
Texas Children's Hospital
2015-2018
The Japanese Society of Gastroenterological Surgery
2016
Hiroshima University
2008
The University of Tokyo
2004
Targeting disialoganglioside (GD2) on neuroblastoma (NB) with T cells expressing a first-generation chimeric antigen receptor (CAR) was safe, but the had poor expansion and long-term persistence. We developed third-generation GD2-CAR (GD2-CAR3) hypothesized that GD2-CAR3 (CARTs) would be safe effective. This phase 1 study enrolled relapsed or refractory NB patients in three cohorts. Cohort received CART alone, cohort 2 CARTs plus cyclophosphamide fludarabine (Cy/Flu), 3 treated CARTs,...
Successful adoptive T-cell immunotherapy of solid tumors will require improved expansion and cytotoxicity tumor-directed T cells within tumors. Providing recombinant or transgenic cytokines may produce the desired benefits but is associated with significant toxicities, constraining clinical use. To circumvent this limitation, we constructed a constitutively signaling cytokine receptor, C7R, which potently triggers IL7 axis unresponsive to extracellular cytokine. This strategy augments...
The successful immunotherapy of acute myeloid leukemia (AML) has been hampered because most potential antigenic targets are shared with normal hematopoietic stem cells (HSCs), increasing the risk sustained and severe toxicity following treatment. C-type lectin-like molecule 1 (CLL-1) is a membrane glycoprotein expressed by >80% AML but absent on HSCs. Here we describe development evaluation CLL-1-specific chimeric antigen receptor T (CLL-1.CAR-Ts) demonstrate their specific activity against...
Chimeric antigen receptor (CAR) T cell therapy for the treatment of acute myeloid leukemia (AML) has risk toxicity to normal cells. CD7 is expressed by leukemic blasts and malignant progenitor cells approximately 30% AML patients but absent on erythroid Since expression also linked with chemoresistance poor outcomes, targeting this may be beneficial subset patients. Here, we show that a CD7-directed CAR in gene-edited (CD7KO) effectively eliminates CD7+ lines, primary AML, colony-forming...
Purpose: The multiple mechanisms used by solid tumors to suppress tumor-specific immune responses are a major barrier the success of adoptively transferred T cells. As viruses induce potent innate and adaptive responses, we hypothesized that immunogenicity could be harnessed for treatment if virus-specific cells (VST) were modified with chimeric antigen receptors (CAR). We tested this hypothesis using VZV-specific (VZVST) expressing CAR GD2, disialoganglioside expressed on neuroblastoma...
Nucleophosmin1 (NPM1) mutations are the most frequently detected gene in acute myeloid leukemia (AML) and considered a favorable prognostic factor. We retrospectively analyzed prognosis of 605 Japanese patients with de novo AML, including 174 NPM1-mutated AML. Although AML showed high remission rate, this was not factor for overall survival (OS); is contrary to generally accepted guidelines. Comprehensive mutation analysis that codon R882 DNA methyltransferase 3A (DNMT3AR882 mutations) were...
Background C-type lectin-like molecule 1 (CLL-1) is highly expressed in acute myeloid leukemia (AML) but absent primitive hematopoietic progenitors, making it an attractive target for a chimeric antigen receptor (CAR) T-cell therapy. Here, we optimized our CLL-1 CAR anti-leukemic activity mouse xenograft models of aggressive AML. Methods First, the using different spacer, transmembrane and costimulatory sequences. We used second retroviral vector to coexpress transgenic IL15. measured...
Although allogeneic hematopoietic cell transplantation (HCT) is an alternative treatment for relapsed or refractory (R/R) acute promyelocytic leukemia (APL), little known regarding the utility of HCT R/R therapy-related APL (t-APL). We retrospectively analyzed data 144 patients with (t-APL, n = 20 and de novo APL, 124) who received a first between 2008 2020. found no significant differences in survival t-APL groups. The 3-year overall (OS) rates were 53.8% group 52.4% group. However, as...
Abstract The outcome of therapy with chimeric Ag receptor (CAR)-modified T cells is strongly influenced by the subset origin infused cells. However, because polyclonally activated acquire a largely CD45RO+CCR7− effector memory phenotype after expansion, regardless origin, it impossible to know which subsets contribute final cell product. To determine contribution naive cell, stem central and terminally differentiated populations CD3 CD28–activated CAR-modified that we use for therapy,...
As the prognosis of relapsed/refractory (R/R) acute myeloid leukaemia (AML) remains poor, novel treatment strategies are urgently needed. Clinical trials have shown that chimeric antigen receptor (CAR)-T cells for AML more challenging than those targeting CD19 in B-cell malignancies. We recently developed piggyBac-modified ligand-based CAR-T target CD116/CD131 complexes, also known as GM-CSF (GMR), juvenile myelomonocytic leukaemia. This study therefore aimed to develop a therapeutic method...
In order to elucidate the mechanism of hyperuricemia in hematologic malignancies, we have retrospectively investigated uric acid metabolism 418 chemotherapy-naïve patients with malignancies. Hyperuricemia was present 116 (27.8%) these on initial hospitalization. Among 65 hyperuricemic analyzed metabolism, six (9.2%) had overproduction type, 52 (80.0%) underexcretion and seven (10.8%) a mixed type. Fourteen (3.3%) developed tumor lysis syndrome patients.
The efficacy of T cells expressing chimeric antigen receptors (CARs) for solid tumors has been limited by insufficient CAR cell expansion and persistence. use virus-specific (VSTs) as carriers CARs may overcome this limitation since CAR-VSTs can be boosted viral vaccines or oncolytic viruses. However, there is understanding the optimal combination endodomains their influence on native receptor (TCR) in VSTs. We therefore compared function GD2.CARs TCR zeta chain (ζ) alone combined with from...
症例は52歳女性．関節リウマチのためメトトレキサートを使用していた．左手脱力で受診しMRIで大脳の多発性病変が認められ，脳生検にてびまん性大細胞型B細胞リンパ腫が証明された．メトトレキサートの使用歴からメトトレキサート関連リンパ増殖性疾患（methotrexate associated lymphoproliferative disorders; MTX-LPD）と診断された．MTX-LPDはMTX休薬のみで改善することが特徴とされるが本例では改善はなく，化学療法の効果も限定的で死に至った．中枢神経のMTX-LPDは非常に稀であるが，免疫抑制剤使用中の合併症の一つとして認知しておく必要がある．
We investigated the potential of nutritional and inflammatory parameters as prognostic factors for follicular lymphoma (FL), also examined predictive value early progression disease within 24 months first-line chemo-immunotherapy (POD24). retrospectively analyzed 46 patients with FL admitted to Teikyo University Hospital treated between May 2009 July 2019. Physical characteristics, blood parameters, markers or scores consumptive/inflammatory conditions were used variables. Nine correlated...
Epstein-Barr-virus- (EBV-) associated lymphoproliferative disorder (LPD) after immunosuppressive therapy for aplastic anemia (AA), in a nontransplant setting, has not been well described. We report one case of colonic EBV-LPD single course AA. The patient developed multiple tumors 3 months receiving therapy, which consisted rabbit antithymocyte globulin (ATG), cyclosporine, and methyl-predonisolone. histological findings biopsy specimens revealed that atypical lymphocytes had infiltrated...